ArticleCardiovascular toxicology2025
CELF1 Promotes Post-myocardial Infarction Cardiac Remodeling Via Suppression of FMO2.
Article in Cardiovascular toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Post-myocardial infarction (MI) cardiac remodeling ultimately causes heart failure. We explored how CUG-binding protein Elav-like family member 1 (CELF1) affected post-MI cardiac remodeling. Mice underwent MI induction by left anterior descending artery (LAD) ligation and short hairpin-CELF1, overexpressing-flavin-containing monooxygenase 2 (FMO2) lentivirus and transforming growth factor-β1 (TGF-β1) treatments. Mouse cardiac fibroblasts were cultured in vitro, followed by fibrosis induction with TGF-β1. Left ventricular ejection fraction, left ventricular end-diastolic volume and left ventricular end-systolic volume were tested by ultrasound cardiography. Heart weight/body weight was determined. CELF1 and FMO2 mRNA levels, pathologic changes, collagen deposition and myocardial fibrosis of cardiac tissues, cardiomyocyte area, myocardial apoptosis, and myocardial CELF1, FMO2, collagen I, fibronectin, and elastin levels were assessed by RT-qPCR, HE, Masson, WGA, TUNEL staining, and immunohistochemistry. CELF1-FMO2 interaction was confirmed using RNAct database and RIP assay. The biotinylated GU-rich element of FMO2 mRNA-CELF1 binding and mRNA stability were assayed by RNA pull-down and actinomycin D assays. LAD ligation induced cardiac remodeling [cardiac enlargement, myocardial tissue damage, increased myocardial collagen fiber tissues, poor cardiac function, cardiomyocyte hypertrophy, myocardial apoptosis, and extracellular matrix (ECM) deposition]. CELF1 was up-regulated in post-MI mouse myocardial tissues. CELF1 silencing up-regulated FMO2 and improved previously-mentioned conditions in MI mice, which were partially reversed by inducing ECM deposition. CELF1 down-regulated FMO2 and promoted FMO2 mRNA decay through interaction with FMO2 and FMO2 mRNA 3'UTR, respectively. FMO2 overexpression improved ECM deposition and cardiac remodeling in MI mice. CELF1 facilitates post-MI cardiac remodeling through FMO2 inhibition.
Indexed as
Identifiers
40021568What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.